News

Vancouver, British Columbia — A highly controlled retrospective analysis suggests that denosumab (Prolia) leads to greater reduction in fracture risk than does zoledronic acid (Reclast) among ...
Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared with denosumab, according to a study data. “While previous observational studies ...
Despite all the buzz about recently-approved osteoporosis drug Prolia (denosumab), Amgen (AMGN) proved at this week's big cancer confab that it has a few other tricks up its sleeves.
A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral density after 15 months of overlapping teriparatide and denosumab therapy, according to a ...
Alvotech. Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and ...
Amgen's bone drug Prolia (denosumab) beat a competitor in an important Phase III prostate cancer trial, but investors remained cautious ahead of challenges elsewhere in the pipeline.
Sandoz has obtained the Food and Drug Administration’s clearance for Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the only FDA-approved denosumab biosimilars, to treat all indications ...
Reddy’ s Laboratories Ltd. and Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S ...
Denosumab (Prolia®, Xgeva®) reversed cortical bone loss and increased bone mineral density, lowering wrist fracture rates in women with osteoporosis, according to new research. Osteoporosis is a ...
FDA Approves Samsung Bioepis’ OSPOMYV™, XBRYK™ (denosumab-dssb), a Biosimilar to Prolia and Xgeva. Share. OSPOMYV™ and XBRYK™ approved by the U.S. Food and Drug Administration ...
Amgen, Inc. AMGN announced positive top-line results from a phase III study on Prolia for use in patients with glucocorticoid-induced osteoporosis..
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpointsProlia® and Xgeva® (denosumab) are ...